AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Exchange: NYSE
- Symbol: ABBV
- CUSIP: 00287Y10
- Previous Close: $61.48
- 50 Day Moving Average: $61.69
- 200 Day Moving Average: $62.54
- 52-Week Range: $1,625,098,000.00 - $52.73
- Trailing P/E Ratio: 17.02
- Foreward P/E Ratio: 9.59
- P/E Growth: 0.78
- Market Cap: $100.38B
- Outstanding Shares: 1,625,098,000
- Beta: 1.57
- Net Margins: 23.22%
- Return on Equity: 141.55%
- Return on Assets: 12.64%
Companies Related to AbbVie:
- Debt-to-Equity Ratio: 5.76%
- Current Ratio: 1.79%
- Quick Ratio: 1.61%
What is AbbVie's stock symbol?
AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."
How often does AbbVie pay dividends? What is the dividend yield for AbbVie?
AbbVie declared a quarterly dividend on Friday, February 17th. Investors of record on Thursday, April 13th will be paid a dividend of $0.64 per share on Monday, May 15th. This represents a $2.56 annualized dividend and a yield of 4.14%. The ex-dividend date is Tuesday, April 11th.
Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?
15 analysts have issued twelve-month price objectives for AbbVie's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate AbbVie's share price to reach $70.20 in the next twelve months.
When will AbbVie announce their earnings?
AbbVie is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about AbbVie stock?
Here are some recent quotes from research analysts about AbbVie stock:
- Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. However, Viekira is facing intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to market. Amgen’s biosimilar version of Humira received FDA approval in Sep 2016. Abbvie could see some of its dominant share in the arthritis market contract when Amgen’s new drug is launched." (9/28/2016)
Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)
Who owns AbbVie stock?
AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.39%), Federated Investors Inc. PA (0.93%), Glenview Capital Management LLC (0.56%), Janus Capital Management LLC (0.53%), Prudential PLC (0.43%) and FMR LLC (0.38%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Thomas A Hurwich, Timothy J Richmond and William J Chase.
Who sold AbbVie stock? Who is selling AbbVie stock?
AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, FMR LLC, Highfields Capital Management LP, Renaissance Technologies LLC, Orbimed Advisors LLC, Loomis Sayles & Co. L P, Franklin Resources Inc. and Nicholas Co. Inc. WI. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Thomas A Hurwich, Timothy J Richmond and William J Chase.
Who bought AbbVie stock? Who is buying AbbVie stock?
AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, State Street Corp, Asset Management One Co. Ltd., Prudential PLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc. and Baird Financial Group Inc..
How do I buy AbbVie stock?
Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AbbVie stock cost?
One share of AbbVie stock can currently be purchased for approximately $61.77.